Jasper Therapeutics, Inc. a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117), as well as novel stem cell transplant conditioning regimes, appointed two pharma industry veteran executives to its regulatory affairs, quality, and clinical operations leadership teams.

Patricia Carlos joins the company as senior vice president of regulatory affairs and quality, and Annette Marcantonio, was appointed vice president of clinical operations.

Carlos has over 25 years of experience in the biotech and pharmaceutical industry, with a proven track record of success in driving global strategy, regulatory affairs, and strategic partnerships. Her expertise spans early development through approval and post-marketing in multiple therapeutic areas. Prior to joining Jasper, she was chief regulatory, Quality and Safety Officer at Agenus, an immuno-oncology company. She also served as senior vice president of regulatory and quality at Arcus Biosciences, where she built out the regulatory, quality and safety functions and led the global regulatory strategy.

Marcantonio has spent more than 30 years in senior clinical operations and development roles, leading large-scale clinical programs in complicated and novel therapeutic areas. Prior to joining Jasper, she served as vice president of clinical operations at Pacylex Pharmaceuticals. Previously, she served as vice. president of clinical affairs at Neurogastrx, where she successfully progressed the NG101 program in Gastroparesis.

At prior companies, Marcantonio was a key participant in the filings of several US and EU marketing applications and held key leadership positions in programs that directly contributed to successful product approvals and label expansions for multiple drugs and biologics.

“With multiple clinical studies of briquilimab in Chronic Spontaneous Urticaria, Low to Intermediate Risk MDS and hematopoietic stem cell transplant either ongoing or planned to start this year, it is the right time to add strength and depth to our regulatory, quality and clinical operations teams,” said Ronald Martell, CEO of Jasper. “Patty and Annette bring decades of experience in guiding drug development programs from investigational new drug application through to successful commercialization, and we are delighted to welcome them to the Jasper organization.”